Activation of Rb and decline in androgen receptor protein precede retinoic acid-induced apoptosis in androgen-dependent LNCaP cells and their androgen-independent derivative.
Androgen ablation-induced prostate cancer regression is transient and ends with the regrowth of androgen-independent (AI) tumors. To mimic this evolution in culture, we chronically deprived an androgen-dependent (AD) prostate cancer cell line (LNCaP) of androgen, generating an AI derivative which retained limited hormone proliferative responsiveness and a barely detectable prostate-specific antigen (PSA) mRNA level. While the cytokeratin 8 (CK8) level was low, the androgen receptor (AR) protein in AI cells was on average tenfold greater than in AD cells. When challenged for susceptibility to undergo apoptosis, the AI cells were more resistant than AD cells to all-trans retinoic acid (tRA) and two chemotherapeutic agents, Taxol and Adriamycin, requiring higher doses and longer periods of treatment to achieve similar effects. Compared to AD cells, the partially apoptosis-resistant AI cells expressed four times more Bcl-2 protein and undetectable levels of p21/WAF1. Induction of apoptosis by tRA in both cell types did not affect their expression but was preceded by the activation of Rb and a pronounced reduction of AR protein level. The kinetics of the Rb activation and AR downmodulation in both cell types matched their tRA sensitivity, suggesting that these events may be required for tRA-induced apoptosis. The results show that the apoptotic pathway in AI cells, although more difficult to induce, is not irrevocably lost and that targeted reduction of the AR protein level with retinoids in combination with androgen ablation therapy may prolong remissions in advanced prostate cancer patients.
Gao
M
M
Department of Medicine, Mount Sinai School of Medicine, New York, New York 10029, USA.
Ossowski
L
L
Ferrari
A C
AC
D000954:Antigens, Surface; D000970:Antineoplastic Agents / Q000494:pharmacology*; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects* / Q000235:genetics; D015153:Blotting, Western; D002268:Carboxypeptidases / Q000032:analysis / Q000235:genetics; D002454:Cell Differentiation / Q000187:drug effects / Q000235:genetics; D002455:Cell Division / Q000187:drug effects / Q000235:genetics; D013196:Dihydrotestosterone / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D015536:Down-Regulation / Q000187:drug effects; D004317:Doxorubicin / Q000494:pharmacology; D005434:Flow Cytometry; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D043425:Glutamate Carboxypeptidase II; D006131:Growth Inhibitors / Q000494:pharmacology; D006801:Humans; D007633:Keratins / Q000032:analysis / Q000235:genetics; D008297:Male; D017239:Paclitaxel / Q000494:pharmacology; D017430:Prostate-Specific Antigen / Q000032:analysis / Q000235:genetics; D011471:Prostatic Neoplasms; D011944:Receptors, Androgen / Q000032:analysis / Q000235:genetics*; D016160:Retinoblastoma Protein / Q000235:genetics*; D014212:Tretinoin / Q000494:pharmacology*; D014407:Tumor Cells, Cultured / Q000737:chemistry / Q000166:cytology / Q000378:metabolism
D000954:Antigens, Surface; D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D006131:Growth Inhibitors; D011944:Receptors, Androgen; D016160:Retinoblastoma Protein; D013196:Dihydrotestosterone; D014212:Tretinoin; D007633:Keratins; D004317:Doxorubicin; D002268:Carboxypeptidases; C473848:FOLH1 protein, human; D043425:Glutamate Carboxypeptidase II; D017430:Prostate-Specific Antigen; D017239:Paclitaxel